IPP Bureau
SciSparc acquires Xylo Technologies' innovative endoscopic portfolio
By IPP Bureau - December 01, 2025
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
SK Biopharmaceuticals acquires exclusive global rights for WARF cancer drug candidate
By IPP Bureau - December 01, 2025
Feinstein Institutes awarded $3.37 million grant to boost first responder mental health
By IPP Bureau - December 01, 2025
The study, titled “A Large-Scale Efficacy Trial of a Resilience Training Program for First Responders,” will enroll 800 first responders in New York and Texas
Lung Cancer Canada and Boehringer Ingelheim team up to transform lung cancer detection
By IPP Bureau - December 01, 2025
Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes
GE HealthCare launches game-changing StarGuide GX for precision nuclear medicine
By IPP Bureau - December 01, 2025
StarGuide GX delivers ultra-high sensitivity and high-resolution imaging, enabling fast, confident diagnostics
Granules India opens advanced Centres of Excellence in Hyderabad
By IPP Bureau - December 01, 2025
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
SAI Parenteral's acquires Australia's Noumed Pharmaceuticals for Rs. 125 Cr
By IPP Bureau - December 01, 2025
MHRA clears inavolisib, offering new option for returning breast cancer
By IPP Bureau - November 30, 2025
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
Europe failing to diagnose HIV early, threatening 2030 AIDS target
By IPP Bureau - November 30, 2025
Gan & Lee Pharma launches Phase 3 trial of once-monthly weight-loss jab
By IPP Bureau - November 30, 2025
InnoCare Pharma launches global Phase II trial of TYK2 inhibitor for prurigo nodularis in China
By IPP Bureau - November 30, 2025
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
a2z wins FDA nod for groundbreaking abdomen-pelvis CT AI Triage system
By IPP Bureau - November 30, 2025
Abdomen-pelvis CT is the nation’s highest-volume CT category
Ascendis Pharma’s FDA review of Achondroplasia drug gets 3-month delay
By IPP Bureau - November 30, 2025
The FDA has classified recent submissions as a major amendment pushing the approval to its NDA for TransCon CNP back three months to February 28, 2026
Biocon Biologics' Drug Substance Facility in Bengaluru cassified as VAI
By IPP Bureau - November 29, 2025
This relates to the manufacture and supply of Human Recombinant Insulin (rh- Insulin) and Biosimilar Pegfilgrastim Drug Substance to the United States
Mangalam Drugs receives Rs. 15 crore repeat export order
By IPP Bureau - November 29, 2025
The receipt of this order further strengthens the company's position in the global pharmaceutical market
